New year, new list: here are the 10 hottest Biotech companies I will watch closely in 2017 and why. This list is not meant to be comprehensive and is in…
Curious about which technologies have attracted the most cash in biotech finance this year? Here's a list of the most impressive cash movements of 2016 in Europe. Believe it or not, 2016…
From the hottest research areas to the most popular city for biotech, which biotech articles have managed to hook our readers the most this year? After an exciting journey of 2…
CureVac has raised an additional €27M ($29.5M) that will help the company keep on its track to be the first one to launch a mRNA therapy, a technology that can…
BioNTech has turned up the heat in the race to bring an mRNA immunotherapy for cancer to the clinic. The German biotech has partnered with American giant Genentech in a…
Moderna is taking Biotech investing to new heights, as it has now increased total fundraising&partnership cash to an unbelievable €1.34Bn ($1.5Bn). It can thank AstraZeneca, which is now adding €126M more…
The collaboration between AstraZeneca and the money-magnet Moderna is giving its first steps. AstraZeneca is filing for authorization of a German Phase I trial, to assess an mRNA therapy for…
Update (05/07/2017): BioNTech has published new results in Nature revealing a strong immune response in all 13 patients treated with its personalized mRNA cancer vaccine, strengthening its potential to become a…
BioNTech is joining its mRNA technology with Bayer's expertise in veterinary applications in a new collaboration - to develop first-in-class vaccines for animals. Based in Mainz (Germany), BioNTech is the…
What if we could send the body an instruction to produce its own drug? That’s what messenger RNA (mRNA) could achieve. A whole new area of therapeutics could be opened.…
Before the end of the mRNA conference in Berlin, I had to interview Stephane Bancel, the French founding CEO of Moderna...one of the biggest deals in Biotech today. Moderna is…
Monday: Leading TCR Immuno-oncology Biotech shows Promising Results against Cancer Tuesday: What the FUGT? We tried the Algae Bar Beer for the TransArt Fest in Copenhagen! Wednesday: Using Algae and NanoTech…
I am still at the mRNA Convention in Berlin...and was invited for a second interview - this time with the 'RNA People', battling to be the first to get an…
Today is the 3rd International mRNA Health Conference in Berlin. I jumped in the metro to go there and interview the most successful people of the field... We first interviewed…
Sanofi is now the latest Biotech lining up to partner with BioNTech from Mainz (Germany), for license of their mRNA Immuno-oncology platform in a€1.37Bn long-term development deal. Novel mRNA targets…
One more hit to Moderna Therapeutics struck by its German competitor CureVac! The Tübingen-based company just announced the opening of its subsidiary in Boston - hometown of Moderna - and a research collaboration with…
mRNA based immunotherapies are no pipe dream anymore. Germany’s CureVac just presented encouraging results of its Phase IIa clinical study. The firm’s lead mRNA candidate CV9103 is well tolerated and…
Everybody has already heard about Boston-based Moderna Therapeutics, the most highly valued venture-backed private Biotech, but CureVac, its German competitor, remains much more understated. This could rapidly change as CureVac just demonstrated that its technology beats Moderna's.…
Last week, Biotech Entrepreneurs gathered in Berlin for the Charité Entrepreneurship Summit 2015. As a spectator, I'll bring you the most important lessons to take on board from successful entrepreneurs. The First speaker…